A Theoretical Framework for the Rational Design of a Scalable Chemoenzymatic Synthesis of Animal-Free Heparin with Pharmaceutical Fidelity

Unfractionated heparin, a vital anticoagulant used in over 100 million doses annually, relies on porcine sources vulnerable to contamination and ethical issues. This theoretical framework proposes a first-principles chemoenzymatic platform for animal-free heparin production, achieving pharmaceutical fidelity through quantum-chemical modeling of enzyme catalysis, stochastic thermodynamics for polymerization control, and algorithmic information theory. The modular cascade includes backbone assembly via PmHS2, N-deacetylation/sulfation with NDST1, epimerization and O-sulfation incorporating 3-OST-1 for antithrombin binding, and real-time QA via Raman-CNN. A novel Glycan Synthesis Fidelity Entropy (GSFE) metric ensures precision (GSFE < 0.1 bits/residue), with economic viability at $120/g (10 kg scale) and regulatory alignment (ICH Q11, FDA, EMA). The self-contained simulation protocol (Psi4, SciPy, SimPy) enables reproducible validation, addressing supply chain risks without external data.